David Bourget (Western Ontario)
David Chalmers (ANU, NYU)
Rafael De Clercq
Jack Alan Reynolds
Learn more about PhilPapers
Public Health Ethics 3 (2):137-146 (2010)
In 2008 New Zealand's pharmaceutical management agency, PHARMAC, made its final decision on the funding of trastuzumab (Herceptin) for HER2-positive early stage breast cancer. PHARMAC declined to fund the 12-month Herceptin regimen requested by the drug's manufacturer, funding instead a 9-week treatment regimen. The decision was justified on the grounds that there was insufficient evidence of additional long-term health benefits from the longer treatment course, which, coupled with the high cost of the drug, did not make the 12-month regimen sufficiently cost-effective. This paper examines the criticism of PHARMAC's decision that ultimately led to the government's decision to expand the health budget in order to fund the 12-month regimen. It defends PHARMAC's decision against the charge of unfairness, arguing that for high-cost drugs with limited proven effectiveness it is not unfair to deny funding on grounds of cost-effectiveness, since although some moral priority must be given to helping those with serious diseases like breast cancer, the capacity of such drugs to swamp health care budgets is itself a significant moral issue. It concludes that the decision to expand the health budget to pay for Herceptin exacerbates rather than solves the political and moral problems involved in prioritizing health care resources
|Keywords||No keywords specified (fix it)|
|Categories||categorize this paper)|
Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
|Through your library|
References found in this work BETA
J. Harris (1987). QALYfying the Value of Life. Journal of Medical Ethics 13 (3):117-123.
Joanna Manning & Ron Paterson (2005). "Prioritization": Rationing Health Care in New Zealand. Journal of Law, Medicine and Ethics 33 (4):681-697.
Citations of this work BETA
No citations found.
Similar books and articles
Ruth McCorkle (1980). An Ethical Dilemma: Information Control in Cancer Care. [REVIEW] Bioethics Quarterly 2 (3):148-158.
Dan Crippen & Amber E. Barnato (2011). The Ethical Implications of Health Spending: Death and Other Expensive Conditions. Journal of Law, Medicine and Ethics 39 (2):121-129.
Lars Bernfort (2003). Decisions on Inclusion in the Swedish Basic Health Care Package—Roles of Cost-Effectiveness and Need. Health Care Analysis 11 (4):301-308.
Bryn Williams-Jones & Michael M. Burgess (2004). Social Contract Theory and Just Decision Making: Lessons From Genetic Testing for the BRCA Mutations. Kennedy Institute of Ethics Journal 14 (2):115-142.
Greg Bognar (2011). Impartiality and Disability Discrimination. Kennedy Institute of Ethics Journal 21 (1):1-23.
Gretchen B. Chapman & Frank A. Sonnenberg (eds.) (2000). Decision Making in Health Care: Theory, Psychology, and Applications. Cambridge University Press.
Claudia Wild (2005). Ethics of Resource Allocation: Instruments for Rational Decision Making in Support of a Sustainable Health Care. Poiesis and Praxis 3 (4):296-309.
Tony Hope, Lars Peter Østerdal & Andreas Hasman (2010). An Inquiry Into the Principles of Needs-Based Allocation of Health Care. Bioethics 24 (9):470-480.
Ruth B. Hoppe (1983). Decision Theory and Health Resource Allocations. Theoretical Medicine and Bioethics 4 (2).
Mary Ann Baily (2011). Futility, Autonomy, and Cost in End-of-Life Care. Journal of Law, Medicine and Ethics 39 (2):172-182.
Added to index2010-08-11
Total downloads9 ( #180,698 of 1,679,339 )
Recent downloads (6 months)1 ( #183,792 of 1,679,339 )
How can I increase my downloads?